SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin inches up on the BSE

24 Feb 2025 Evaluate

Lupin is currently trading at Rs. 1906.65, up by 0.50 points or 0.03% from its previous closing of Rs. 1906.15 on the BSE.

The scrip opened at Rs. 1905.25 and has touched a high and low of Rs. 1945.45 and Rs. 1878.75 respectively. So far 29898 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2403.45 on 02-Jan-2025 and a 52 week low of Rs. 1493.75 on 04-Jun-2024.

Last one week high and low of the scrip stood at Rs. 2031.65 and Rs. 1878.75 respectively. The current market cap of the company is Rs. 86747.37 crore.

The promoters holding in the company stood at 46.95%, while Institutions and Non-Institutions held 46.79% and 6.26% respectively.

Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its manufacturing facility in Somerset, New Jersey, for the inspection conducted from January 27 to January 31, 2025. 

Earlier, the company had received ‘A-’ leadership rating from CDP for its outstanding performance in climate change and water security. This rating reflects Lupin's leadership in environmental transparency and performance and underscores the strategic and systematic efforts in its sustainability journey.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2326.50 -12.70 (-0.54%)
16-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1693.15
Dr. Reddys Lab 1221.25
Cipla 1230.75
Zydus Lifesciences 939.20
Lupin 2326.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×